文献速递慢性肾脏病

质子泵抑制剂使用与慢性肾脏病患者骨折风险的相关性

Proton pump inhibitor use and bone fractures in patients with chronic kidney disease.
PubMed 文献 · Nephrol Dial Transplant · 2024-01-01

本研究基于IQVIA疾病分析数据库开展人群病例对照研究,匹配6076例有骨折与6076例无骨折的慢性肾脏病患者。结果显示质子泵抑制剂使用与骨折风险升高相关(OR 1.68;95%CI 1.55-1.83),60岁以下且PPI处方超过2年者关联最强(OR 6.85;95%CI 1.85-25.38)。结论提示对无适应症者停用PPI或可降低骨折风险。

要点

  • 慢性肾脏病患者使用PPI与骨折风险升高相关,OR为1.68。
  • 60岁以下且PPI使用超过2年者骨折风险最高,OR达6.85。
  • 对无适应症的CKD患者停用PPI可能是可干预的骨折风险因素。

核心结论

  • 在慢性肾脏病患者中,质子泵抑制剂使用与骨折风险增加相关。

研究设计与样本

  • 基于IQVIA疾病分析数据库的人群观察性病例对照研究。
  • 纳入慢性肾脏病患者,按1:1最近邻倾向评分匹配有骨折与无骨折者各6076例。

主要发现

  • 总队列中PPI使用与骨折风险升高相关(OR 1.68;95%CI 1.55-1.83)。
  • 该关联见于几乎所有骨折类型。
  • 60岁以下且PPI处方超过2年者关联最强(OR 6.85;95%CI 1.85-25.38)。
  • PPI使用与骨折的关联在男女之间无差异。

临床怎么用

  • 对无明确适应症的慢性肾脏病患者,可考虑停用PPI以降低骨折风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with chronic kidney disease (CKD) are at high risk for bone fractures, which are associated with high morbidity and mortality. Proton pump inhibitors (PPI) have been linked to an increased risk for fractures in the general population as well as in patients with need for hemodialysis, but studies in patients with CKD are currently missing. METHODS: We performed a population-based observational case-control study exploring a sample of patients with CKD derived from the IQVIATM Disease Analyzer database. Patients with and without fractures were matched using the 1:1 nearest neighbor propensity score matching method. To investigate the association between PPI use and fractures, multivariable logistic regression analyses were performed adjusting for confounding factors. RESULTS: In total, 6076 patients with and 6076 patients without fractures were matched and subsequently available for analyses. In the total cohort, PPI use was associated with an increased risk for fractures [odds ratio (OR) 1.68; 95% confidence interval (95% CI) 1.55-1.83]. This association was noted for nearly all types of fractures. The strongest association between PPI use and fractures was found in patients below the age of 60 years with a PPI prescription for longer than 2 years (OR 6.85; 95% CI 1.85-25.38). The same was true when analyzing cumulative PPI doses. Here, patients below the age of 60 years with a cumulative PPI dose above 16 000 mg (highest quartile) had the highest risk for fractures (OR 4.62; 95% CI 1.87-11.44). There was no difference between men or women regarding the association between PPI use and fractures. CONCLUSIONS: This study provides evidence that PPI use is associated with fractures in patients with CKD. Deprescription of PPI in patients without an indication for treatment could be a modifiable risk factor to reduce fracture risk in this high-risk group.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Kommer A, Kostev K, Schleicher EM, et al. Proton pump inhibitor use and bone fractures in patients with chronic kidney disease. Nephrol Dial Transplant. 2024. PMID: 39025803. doi:10.1093/ndt/gfae135

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。